English
Français
Deutsch
Italiano
Português
Русский
Español
ไทย
Türkçe
简体中文
日本語
한국어
हिन्दी
Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 12 | 8 | 3 | 0 | 0 |
| Last 30D | 2 | 2 | 1 | 0 | 0 |
| 1M Ago | 4 | 2 | 0 | 0 | 0 |
| 2M Ago | 4 | 4 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 2 | 0 | 0 |
In the last 3 months, 23 analysts have offered 12-month price targets for Biogen. The company has an average price target of $331.48 with a high of $379.00 and a low of $263.00.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
